← Two worldsExplore the chapters ↗︎

GOVERNANCE AT THE THRESHOLD · ABOUT ONE MINUTE

The research, at a glance.

The question: Are biotech companies with more investor representatives on their boards at IPO acquired sooner?

THE MAIN FINDING

A 20.7-percentage-point higher investor share of board seats was associated with 1.5× the acquisition rate among companies still at risk. The rounded 95% confidence interval was 1.2–1.9. This is an association, not proof that the directors caused a sale.

THE OWNERSHIP CAVEAT

After adding disclosed investor ownership, the estimate fell to 1.3×. It was significant on the main coding but not robust across reasonable checks. Whether board seats add reliable information beyond ownership remains unestablished.

The scope: 349 North American biotech companies listed in 2015–2021; 99 were acquired by 25 September 2026. These results do not predict an individual company’s sale or establish a cause. Europe is an incomplete, descriptive extension.

Explore the full research ↗︎Thesis and annexes

Yashasvee Chandra · ESCP Business School · Sources and credits

ABOUT THE RESEARCH

Frequently asked questions

Why study companies that listed between 2015 and 2021?

This period provides a sizeable group of biotech listings, with several years to observe what happened afterwards. The frame has 452 companies: 349 in North America and 103 in Europe. The listing window ends in 2021; outcomes are followed through 25 September 2026.

Why use SEC filings?

They are public documents that name directors, major shareholders and the connections between them. The ownership footnotes help establish which investor a director represents. SEC filings cover the US-listed companies; European home-listed companies required other sources.

Why study listed companies rather than private ones?

The question concerns what happens after an IPO. Listing provides a common starting point and detailed disclosures. Private companies, and companies acquired before completing an IPO, fall outside this study.

Read all 24 questions